How to Select a Local Agent for Overseas Registration of IVD Products?

Published: 2026-07-29 | Updated: 2026-07-29

Selecting a local agent is a critical step in the overseas registration of IVD products. Companies must evaluate the agent's legal responsibilities based on the target country's regulatory requirements (e.g., Authorized Representative for EU CE-IVDR, In-country Representative for Brazil ANVISA, Local Representative for Saudi SFDA), and assess their technical expertise, compliance experience, and coverage. Core steps include: confirming product classification under medical device regulations, determining risk class and registration pathway, assessing reusability of existing NMPA, CE, FDA, or MDSAP documentation, identifying technical files requiring localization (performance validation, risk management, clinical evidence, labeling), and focusing on the agent's control over certificates, change notification, and post-market maintenance. Common risks include agents lacking substantive capability, document translation errors, and delays in renewal. It is recommended to prioritize agents with IVD expertise and multi-country registration experience, request clear service agreements and fee structures, and include IP protection and transition support in contracts.

Applicable Scenarios and Core Issues

When planning to export IVD products to GHWP member countries (e.g., Brazil, Saudi Arabia, ASEAN nations) or other markets requiring local representation, the choice of local agent directly impacts registration success. The core issue is whether the agent has the legal qualification as the registration holder, can handle localization of technical documents, performance evaluations, and clinical evidence, and assumes post-market surveillance and vigilance responsibilities. The agent is not merely a communicator but the legal responsible entity for the product in that country.

Different countries define the agent's responsibilities differently. For example, the EU CE-IVDR requires the Authorized Representative to bear joint liability for product compliance and manage UDI and vigilance systems; Brazil ANVISA requires the In-country Representative to hold a GMP certificate and participate in registration applications; Saudi SFDA requires the Local Representative to have a quality management system and handle import customs clearance. Companies must first identify the target market and then select an agent accordingly.

Registration Judgment Logic

Step 1: Determine Product Classification

Confirm whether the product falls under medical device regulations in the target country. For instance, some rapid diagnostic kits may be classified as drugs or eligible for exemptions.

Step 2: Identify Risk Class

Determine the risk class (e.g., IVDR A/B/C/D, ANVISA I/II/III/IV, SFDA classification) to define the registration pathway (self-declaration vs. notified body review).

Step 3: Assess Reusability of Existing Documentation

If NMPA registration, CE certification, or FDA 510(k) clearance exist, use them as baseline for gap analysis. Note that clinical evaluation reports, stability data, and risk management reports typically require adaptation to target population and standards.

Step 4: Define Required Technical File Package

Includes product description, design verification reports, performance evaluations (e.g., analytical sensitivity, specificity), stability studies, clinical evidence (clinical trials or literature reviews), labels and instructions for use (IFU), and ISO 13485 or MDSAP certificates.

Step 5: Confirm Post-Market Support

Ensure the agent provides services such as adverse event reporting, change notifications, certificate renewal, and Periodic Safety Update Reports (PSURs).

Documentation and Evidence

Companies must provide the agent with a complete technical documentation set, including:

• Product technical specifications and intended purpose statement
• Analytical performance study reports (e.g., per CLSI or local guidelines)
• Stability data (real-time and accelerated)
• Risk management file (per ISO 14971)
• Clinical evidence (clinical trial reports, literature reviews, or usage experience evidence)
• Labels, IFU, and packaging samples (translated into local language)
• Quality management system certificate (ISO 13485 or MDSAP)
• Manufacturing information (factory address and GMP status)

The agent should provide proof of qualification (e.g., authorization registration certificate, business scope, successful case history) and sign a service agreement defining responsibilities.

Common Mistakes

The most frequent mistake is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local liability. Other common errors include:

• Direct translation of NMPA documents without restructuring evidence per target market pathway.
• Multiple model variants but insufficient test reports, clinical evidence, or label coverage.
• Selecting a local agent based solely on sales cooperation without clarifying regulatory responsibilities, certificate control, and post-market maintenance.
• Inconsistent claims among labels, IFUs, promotional materials, and registration dossiers, leading to deficiencies or post-market compliance risks.
• Failing to plan for multi-country document reuse, resulting in duplicated efforts and extended timelines for each country.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm documentation readiness and avoid discovering critical evidence gaps after submission.

• Compile a product list, model matrix, and intended use statements.
• Verify reusability of existing NMPA, CE, FDA, or other market registration documents.
• Prepare ISO 13485 certificates, test reports, risk management files, clinical evaluations, and English IFUs.
• Confirm the local agent's responsibilities, fees, certificate control, and exit mechanisms.
• Create a target country gap assessment table specifying additional testing, translation, notarization, or supplementary declarations required.

AIMEILI’s Perspective

Companies often mistakenly view the agent as a mere document courier, but the agent is the legal representative bearing regulatory liability in the target country. Early project phases should focus on evaluating the agent’s technical understanding and regulatory communication experience, not just cost. Most technical documents (e.g., risk management, performance evaluations) can reuse NMPA or CE materials, but localization is required (e.g., Brazil ANVISA requires CVs and clinical data per local regulations). Agent selection directly affects certificate control—if the agent fails to cooperate on changes or renewals, the company could lose the entire market. For multi-country registrations, it is advisable to choose group agents covering multiple target markets or establish a unified document management platform to reduce rework and deficiency risks.

Frequently Asked Questions

Does the agent need to hold ISO 13485 or other system certifications?

Not necessarily. Most countries only require the agent to have legal business qualifications and regulatory registration. However, some high-risk IVD products (e.g., Class D) may require the agent to participate in quality system audits. It is recommended to choose agents with system certifications or experience working with notified bodies.

How to determine if an agent has IVD product experience?

Request at least three successful registration cases of similar products and verify public records from the target country’s regulatory authority. Ask whether the agent’s technical team has IVD regulatory background and has participated in IVDR or equivalent projects.

What are the key clauses in the agent contract?

Must include: scope of services (registration, maintenance, changes, vigilance), fee structure (one-time plus annual maintenance), IP ownership, certificate control, data confidentiality, exit mechanisms, and transition support. Consider adding performance clauses, such as registration timelines and limits on deficiency responses.

Quality System and Evidence Consistency

From a regulatory review perspective, quality system documents are not standalone certificates. Regulators often check consistency among manufacturer name, production address, product scope, certificate validity, applicable standards, and technical files. If the ISO 13485 certificate scope does not match the product, or if addresses, model numbers, or IFU versions conflict with test reports, additional explanations may be required even with extensive documentation.

Companies should create an evidence consistency checklist before submission, cross-referencing product names, models, intended uses, applicable standards, test report numbers, clinical evaluation conclusions, risk management versions, IFU versions, and quality system certificates. This basic step significantly reduces deficiency rates, especially for projects involving multiple GHWP member countries or product families.

Localization and Agent Responsibilities

Target market registration projects typically involve local agents, authorized representatives, importers, or registration holders. Companies need to confirm whether the local partner only submits documents or also handles regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFUs, and authorization documents cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warning statements, storage conditions, UDI or traceability requirements, importer information, authorized representative details, and after-sales contact information. For companies with existing CE, FDA, or NMPA documentation, the key is to convert reusable evidence into an acceptable submission structure for the target country, not to rewrite a completely new document set.

Post-Market Maintenance and Long-Term Planning

Registration completion does not end compliance obligations. Companies must manage certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall processes, label versions, and regulatory update records. Many companies invest heavily in the registration phase but neglect post-market maintenance, leading to disconnects between certificates and market sales (e.g., after a manufacturing address change, model expansion, IFU update, or agent replacement).

AIMEILI recommends incorporating this issue into annual international registration planning: prioritize target markets, build reusable documentation packages and country gap lists, and schedule submissions, deficiency responses, post-market maintenance, and renewal milestones. This approach not only improves individual registration efficiency but also develops a reproducible export compliance capability, reducing costs of starting from scratch when entering new markets.